EYP-1901 for Retinal Exudative Diseases

An overview of the current status of the EYP-1901 clinical trial program in wet AMD and DME, presented at Hawaiian Eye and Retina 2026

1

EYP-1901 is a novel treatment for retinal exudative diseases, offering sustained release of vorolanib with reduced treatment burden.
2

EYP-1901 demonstrated statistical noninferiority to aflibercept in improving best-corrected visual acuity in Phase 2 trials.
3

Ongoing Phase 3 trials LUGANO and LUCIA aim to confirm EYP-1901's safety and efficacy in wet AMD with 6-month redosing.
4

EYP-1901 has shown a favorable safety profile across completed clinical trials, with no significant safety signals reported.
5

Preparations for pivotal Phase 3 trials in diabetic macular edema are underway, following positive results from earlier trials.

The Ophthalmologist

1